Abstract
Single-step selection with vinblastine was performed in populations of the human sarcoma cell line MES-SA, to assess cellular mechanisms of resistance to the drug and mutation rates via fluctuation analysis. At a stringent selection with 20 nM vinblastine, resulting in 5–6 logs of cell killing, the mutation rate was 7 × 10–7per cell generation. Analysis of variance supported the hypothesis of spontaneous mutations conferring vinblastine resistance, rather than induction of adaptive response elements. Surviving clones displayed a stable multidrug resistance phenotype over a 3-month period. All propagated clones demonstrated high levels of resistance to vinblastine and paclitaxel, and lower cross-resistance to doxorubicin and etoposide. Activation of MDR 1 gene expression and P-glycoprotein function was demonstrable in all clones. No elevation was found in the expression of the mrp gene, the LRP-56 major vault protein and β-tubulin isotypes (M40, β4, 5β, and β9) in these mutants. We conclude that initial-step resistant mechanism in these vinblastine-selected mutants commonly arises from a stochastic mutation event with activation of the MDR 1 gene. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Baker RM, Burnette DM, Mankovitz R, Thompson LH, Whitemore GF, Siminovitch L and Till JE (1974) Ouabain-resistant mutants of mouse and hamster cell in culture. Cell 1: 9–21
Beketic-Oreskovic L, Durán GE, Chen G, Dumontet C and Sikic BI (1995) Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593–1602
Boesen JJ, Niericker MJ, Dieteren N and Simons JW (1994) How variable is a spontaneous mutation rate in cultured mammalian cells?. Mutat Res 307: 121–129
Cabral F and Barlow SB (1989) Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB J 3: 1593–1599
Catcheside DG (1951) The Genetics of Micro-Organisms, pp. 158–163. Sir Isaac Pitman & Sons Ltd: London
Chen G, Jaffrézou J-P, Fleming WH, Durán GE and Sikic BI (1994) Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res 54: 4980–4987
Chen G, Durán GE, Steger KA, Lacayo NJ, Jaffrézou J-P, Dumontet C and Sikic BI (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem 272: 5974–5982
Cole J, Arlett CF and Green MH (1976) The fluctuation test as a more sensitive system for determining induced mutation in L5178Y mouse lymphoma cells. Mutat Res 41: 377–386
Crawford BD, Barrett JC and Ts'o OP (1983) Neoplastic conversion of proneoplastic Syrian hamster cells: rate estimation by fluctuation analysis. Mol Cell Biol 3: 931–945
Dumontet C and Sikic BI (1999) Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061–1070
Dumontet C, Durán GE, Steger KA, Beketic-Oreskovic L and Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56: 1091–1097
Fisher GA and Sikic BI (1995) Clinical studies with modulators of multidrug resistance. In Drug Resistance in Clinical Oncology and Hematology. Hematology/Oncology Clinics of North America, Vol. 9, No. 2. Fisher GA, Sikic BI (eds) pp 363–382. WB Saunders Co: Philadelphia
Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T and Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118–17125
Goldie JH and Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733
Gottesman MM (1993) How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747–754
Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD and Horwitz SB (1995) Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270: 31269–31275
Harker WG and Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 4091–4096
Harker WG, MacKintosh FR and Sikic BI (1983) Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res 43: 4943–4950
Jaffrézou J-P, Chen G, Durán GE, Kuhl JS and Sikic BI (1994) Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst 86: 1152–1158
Kendal WS and Frost P (1988) Pitfalls and practice of Luria–Delbrück fluctuation analysis: A review. Cancer Res 48: 1060–1065
Kimmel M and Axelrod DE (1994) Fluctuation test for two-stage mutations: application to gene amplification. Mutat Res 306: 45–60
Ling V (1992) P-glycoprotein and resistance to anticancer drugs. Cancer 69: 2603–2609
Luria SE and Delbrück M (1943) Mutations of bacteria from virus sensitive to virus resistance. Genetics 28: 491–511
Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L and Chen G (1997) Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40: S13
Tlsty TD, Margolin BH and Lum K (1989) Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. Proc Natl Acad Sci USA 86: 9441–9445
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Chen, G., Durán, G., Mangili, A. et al. MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer 83, 892–898 (2000). https://doi.org/10.1054/bjoc.2000.1371
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1371
Keywords
This article is cited by
-
Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
World Journal of Urology (2019)
-
Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7
Tumor Biology (2014)
-
Microtubule-binding agents: a dynamic field of cancer therapeutics
Nature Reviews Drug Discovery (2010)